ZA984573B - Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561lck tyrosine kinases - Google Patents

Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561lck tyrosine kinases

Info

Publication number
ZA984573B
ZA984573B ZA984573A ZA984573A ZA984573B ZA 984573 B ZA984573 B ZA 984573B ZA 984573 A ZA984573 A ZA 984573A ZA 984573 A ZA984573 A ZA 984573A ZA 984573 B ZA984573 B ZA 984573B
Authority
ZA
South Africa
Prior art keywords
p561lck
quinoline
growth factor
derived growth
tyrosine kinases
Prior art date
Application number
ZA984573A
Inventor
Alfred P Spada
Wei He
Michael R Myers
Martin P Maguire
Original Assignee
Rhone Poulenc Rorer Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Pharma filed Critical Rhone Poulenc Rorer Pharma
Publication of ZA984573B publication Critical patent/ZA984573B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA984573A 1997-05-28 1998-05-28 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561lck tyrosine kinases ZA984573B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86445597A 1997-05-28 1997-05-28

Publications (1)

Publication Number Publication Date
ZA984573B true ZA984573B (en) 1999-01-21

Family

ID=25343315

Family Applications (3)

Application Number Title Priority Date Filing Date
ZA984573A ZA984573B (en) 1997-05-28 1998-05-28 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561lck tyrosine kinases
ZA984571A ZA984571B (en) 1997-05-28 1998-05-28 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561lck tyrosine kinases
ZA984572A ZA984572B (en) 1997-05-28 1998-05-28 Quinoline and quinoxaline compounds which inhibit platelet-derived growth facto and/or p56ick tyrosine kinases

Family Applications After (2)

Application Number Title Priority Date Filing Date
ZA984571A ZA984571B (en) 1997-05-28 1998-05-28 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561lck tyrosine kinases
ZA984572A ZA984572B (en) 1997-05-28 1998-05-28 Quinoline and quinoxaline compounds which inhibit platelet-derived growth facto and/or p56ick tyrosine kinases

Country Status (4)

Country Link
KR (1) KR100480360B1 (en)
CN (1) CN101293869A (en)
UA (2) UA66361C2 (en)
ZA (3) ZA984573B (en)

Also Published As

Publication number Publication date
ZA984571B (en) 1999-01-21
CN101293869A (en) 2008-10-29
ZA984572B (en) 1998-12-03
UA66362C2 (en) 2004-05-17
KR100480360B1 (en) 2005-04-06
UA66361C2 (en) 2004-05-17
KR20010013059A (en) 2001-02-26

Similar Documents

Publication Publication Date Title
IL133007A0 (en) Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
PL348605A1 (en) Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors
IL143406A0 (en) Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors
IL143405A0 (en) Quinoline and quinoxaline compounds
IL134013A (en) Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
PL331154A1 (en) Bicyclic heteroaromatic compounds as inhibitors of proteinous tyrosine kinase
IL127796A0 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
HK1035188A1 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
IL142092A0 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
IL137041A0 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
HU9602017D0 (en) Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor
ZA200108015B (en) Substituted 3-cyano-[1.7], [1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases.
ZA984573B (en) Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561lck tyrosine kinases
AU2876000A (en) Tyrosine kinase inhibitors and methods of using the same
HUP0002219A3 (en) Quinoline and quinoxaline derivatives which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases and pharmaceutical compositions containing them
ZA9710727B (en) Substituted pyrimidine compounds and methods of use.
ZA987649B (en) Imidazoquinoxaline protein tyrosine kinase inhibitors.